BioCentury
ARTICLE | Clinical News

Cabiralizumab in Phase II for pancreatic cancer, Five Prime receives $25M milestone

February 2, 2018 8:19 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) began a Phase II trial to evaluate cabiralizumab (FPA008) plus Opdivo nivolumab with and without chemotherapy in patients with locally advanced or metastatic pancreatic cancer that progressed during or after one line of chemotherapy. The trial start triggered a $25 million payment to Five Prime Therapeutics Inc. (NASDAQ:FPRX) under a 2015 deal, which granted BMS an exclusive, worldwide rights to Five Prime's colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) antibody program, including cabiralizumab (see BioCentury, Oct. 19, 2015).

The open-label, U.S. trial is to enroll about 160 patients to receive investigator's choice of chemotherapy or cabiralizumab plus Opdivo as doublet therapy or in combination with gemcitabine and Abraxane nab-paclitaxel or oxaliplatin, 5-fluorouracil and leucovorin. Progression-free survival (PFS) is the primary endpoint. Secondary endpoints include pharmacokinetics, objective response rate (ORR), median duration of response, overall survival (OS) rate and safety...